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Abstract
Hepatitis delta virus (HDV) is a defective RNA virus that requires HBsAg for replication and trans-
mission. It can cause acute or chronic hepatitis. Chronic infection with HDV is one of the most 
severe and difficult to treat forms of viral hepatitis. It has been estimated that there is a total of 15-20 
million HDV carriers in the world. This review focuses on two fundamental aspects of HDV infec-
tion. On the one hand, epidemiological data are summarized, which are essential to understand 
the real burden of this disease. After the HBV vaccination programs in many countries all over the 
world, HDV infection has decreased since 1980’s but this decline has not continued further in the 
last decade. Therefore, HDV infection is still an important public health problem in the world. On 
the other hand, therapeutic options are described. Currently, interferons are the only option for the 
treatment of chronic hepatitis delta infection, and pegylated-interferons have shown better results 
than conventional interferons (IFNs). Monotherapy of nucleos(t)ide analogs have been found inef-
fective against the HDV infection, but adefovir and pegylated-IFN combination therapy have had 
some advantages for reduction of HBsAg levels. Trials with more potent nucleoside analogs and 
pegylated-IFN could be effective in the treatment of chronic HDV infection. New agents like prenyl-
ation inhibitors, that can affect the interactions between the large HDV antigen and HBsAg in the 
HDV virion, will be a hope in treatment of HDV infection.
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Introduction
Hepatitis delta virus (HDV) is a defective RNA virus which needs hepatitis B virus (HBV) for replica-
tion and transmission. Chronic infection with HDV is known as the worst form of viral hepatitis in 
humans [1-3]. It can also cause acute infection as coinfection with HBV or superinfection in HBV 
carriers.
Delta antigen was first described by Mario Rizzetto and colleagues in the nucleus of hepatocytes de-
rived from patients infected with HBV. They detected this antigen particularly during the severe course 
of HBV infection. The disease was associated with a particle consisting of an RNA genome which was 
encapsidated by HBV envelope proteins. This particle, named “delta agent” or “HDV”, was identified as 
the infectious agent causing hepatitis in the presence of HBV infection [4].
Virology
The HDV virion is approximately 36 nm in diameter. It has an outer coat containing the three HBV 
envelope proteins termed large, medium and small hepatitis B surface antigen (HBsAg) and host lip-
ids. The HDV virion has an inner nucleocapsid consisting of a single stranded, circular RNA of 1679 
nucleotides and about 200 molecules of hepatitis D antigen (HDAg) per genome [5]. HDAg is the only 
protein that is encoded by the HDV genome. HDAg has major isoforms termed small and large. Small 
HDAg (24 kDa) with 195 amino acids accelerates HDV-RNA synthesis, whereas large HDAg (27 kDa) 
with 214 amino acids inhibits HDV-RNA synthesis but is necessary for virion structure [3,5].
The virion attaches to the hepatocyte membrane receptor with large HBsAg. The virion is uncoated 
after entering the hepatocyte. The nucleocapsid is translocated to the nucleus. The HDAg has no RNA 
polymerase activity to replicate the genome, therefore the genomic strand is replicated by the host RNA 
polymerase [5-7].
Epidemiology
HBV infection is a serious health problem: there are over 350 million people with chronic hepatitis B 
around the world. It has been estimated that approximately 5% of all HBsAg carriers are also coinfected 
with HDV, leading to a total 15-20 million HDV carriers in the world [2,3,6,7]. The virus is highly 
endemic in Mediterranean countries, the Middle East, Central Africa and northern parts of South 
America [3]. Generally, HBV and HDV infections don’t exist in parallel: the rate of HDV infection is 
not a simple reflection of HBV infection, and other factors, such as age during HBV infection, could 
determine the occurring of HDV infection. In Southern Europe, before HBV vaccination programs 
the prevalence of HDV infection was more than 20% in the 1980’s. This prevalence has significantly 
decreased to 5-10% after 1980. After 1995, HDV positivity rates in chronic HBV infection were 4.8%, 
12.1%, 23.5%, 27.1% for Western, Middle, East and Southeastern regions in Turkey, respectively [8]. In 
Mongolia, the etiology of one third of chronic hepatitis infections is HDV infection [9].
HDV is transmitted in the same way as HBV, mainly parenteral route, whereas vertical transmission 
from mother to newborn is rare. There is a high prevalence of HDV infection in parenteral drug ad-
dicts in Western countries. Household transmission is also possible [10,11]. High-risk groups include 
HBsAg-positive parenteral drug users, female prostitutes and brothel-goers. In recent decades, male 
prostitutes and immigrant prostitutes have also entered high-risk population groups and may become 
reservoir for disease transmission in HBV endemic areas [12].
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There are many reports about the prevalence of HDV infection, but they are difficult to interpret. In 
most reports, the local HDV prevalence is restricted to patients with chronic hepatitis B or cirrhosis, 
not including asymptomatic HBsAg carriers, or to special populations, as intravenous drug addicts, 
homosexuals, and prostitutes [8-10,12-15]. Therefore reports have not been representative of the whole 
population of HBsAg carriers in terms of HDV infection [16].
Epidemiologic studies will be discussed according to different geographic areas below.
The prevalence rate of HDV infection in asymptomatic HBV carriers was reported as 2%, 31%, and 
3.3% in Jordan, Kuwait, and Saudi Arabia, respectively [17-19]. In chronic liver diseases, it was re-
ported as 23.5%, 23%, 2%, and 10% in Egypt, Jordan, Yemen, and Iran respectively [15,17,20-22]. The 
prevalence of HDV infection was low (0.5% to 13.3%) in Japan except in some islands of Okinawa, 
Russia except in Yakutia (18-20%), Korea, Indonesia (< 0.05%), Malaysia, Thailand (0.7%), Philippines 
and Vietnam (1.3%), and Lebanon (1.2%) [22]. In Japan, the prevalence of antibodies against HDV 
(anti-HDV) ranges from 21.3% to 63.3% in Okinawa: these high figures are due to older HBV carriers, 
and reflect previous acquirement of HDV infection in that cohort [23]. Taiwan was endemic for hepa-
titis B before vaccination [22]. From June 1983 to May 1995, similarly to the decline in HBV infection, 
the HDV prevalence in HBsAg carriers decreased considerably to 4.4% [24]. But, in 2003, the HDV 
prevalence in HBsAg carriers was detected as 15.3% in Southern Taiwan [25]. In Pakistan, prevalence 
of HDV in HBsAg-positive patients is very high (up to 69%) [26].
In China, although the prevalence of HBV infection is high, HDV infection is not very prevalent. There 
are some differences across the regions of China. In Shijiazhuang, HDV prevalence rate was 12.9%, 
whereas in Hong Kong it was 0.15% in HBV carriers [27,28].
In Saudi Arabia, HDV prevalence in HBsAg carriers was 8% and 3.3% in 1986 and 2004, respectively 
[29,30]. Similarly to many other countries, HDV infection is expected to decrease in Saudi Arabia due 
to global vaccination program for HBV [30].
In our country, HDV infection is still an important health problem, particularly southeast and east part 
of Turkey. Degertekin et al. evaluated the 62 studies about the HDV infection from different centers in 
several regions of Turkey for epidemiology of HDV infection [31]. Anti-HDV positivity was detected 
in 20% of 5961 patients with chronic HBV infection and in 32% of 1264 patients with HBV cirrhosis, 
respectively. The positivity rate was significantly lower in Istanbul and Izmir (west part of Turkey) com-
pared to Diyarbakır and Van (Southeast and East of Turkey). This difference could be related to multi-
membered family structure with close contact, unavailability of HBV vaccine, use of non-disposable 
injectors in the past, poor circumstantion and shortage of health services and sanitation in the East 
and Southeast of Turkey in the past [31]. This meta-analysis of 30 studies, which included large study 
groups for the epidemiology of HDV, showed that HDV infection in chronic HBV infection had de-
creased from 29% to 12% in central Anatolia and from 37% to 27% in Southeast of Turkey after 1995. 
It is probably related to the universal vaccination program in 1998, the preventive public health issues, 
and the improved socioeconomic status but it is still a really hard problem in our country. We hope this 
decline in HDV infection will continue.
The rate of anti-HDV seropositivity was found equal to 2.7% among subjects positive for HBsAg in a 
recent epidemiologic population-based study in 5471 subjects representing the Turkish population [32].
In Europe, HDV infection has predominated in the Mediterranean basin, in the Balkan Peninsula, ex 
Soviet Union. Highest European rates in terms of anti-HDV positivity were 95% and 80% in Romania 
and ex Soviet Union, respectively, in the 1980’s [33,34]. Countries such as Denmark, Sweden, Norway 
in Northern Europe have low rates of HBV infection, but relatively high HDV prevalence could be 
detected in special high-risk groups. Since 1990’s, HDV infection has decreased significantly in Europe 
[35,36]. In sequential surveys in Italy, rate of anti-HDV seropositivity was found equal to 24.6% in 1983 
[37], 14% in 1992 [38], and 8.3 in 1997 [39]. A similar decreasing rate in HDV seropositivity was also 
seen in Spain [40]. Unfortunately this decline has not continued in the last decade [41]. The prevalence 
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of HDV detected in 21 Italian centers in 2006 was 8.1% (95 of 1179 patients); this rate was similar to the 
prevalence in 1997 [42]. Gaeta et al. thought that besides vaccination programs against HBV infection, 
the huge mortality for human immunodeficiency virus (HIV) infection before 1996 had caused the 
rapid reduction of patients with HBV and HDV infection. After active antiretroviral therapy in 1996, 
the mortality due to HIV infection had decreased but morbidity and mortality due to liver disease had 
increased [39]. The picture is similar in Northern Europe, HDV prevalence was about 8.5% from 2000 
to 2006 in London [43] and 8-10% in Germany since 1997 [3,44]. In both countries, the majority of 
HDV patients were immigrants from highly endemic areas. The patients (258) with HDV infection in 
Hannover have presented in a high frequency with an advanced stage of liver disease and the course 
of disease did not differ between Turkish-born, Eastern European-born and German born patients 
[45]. In France, HDV is not vanishing, maybe due to immigrants from Africa [46]. The course of HDV 
infections may reveal a wide clinical spectrum ranging from asymptomatic carriage of the virus to very 
severe disease in Greece [47].
There is limited epidemiology data on hepatitis D in the United States. Prevalence of HDV in US was 
reported up to 30% in patients with HBV infection [48], 2% in homosexual men [49] in 1989 and in 
around 20% in hemophiliacs [50] in 1993. HDV infection is now a vanishing disease in the US and 
Canada and in many American countries and the problem of HDV infection is almost restricted to 
intravenous drug users. On the other hand, hepatitis D is prevalent in HBsAg-positive patients in 
Amazonia. Very high frequencies of HDV infection and high morbidities and mortalities are described 
in the Amazonian region of Western Brazil [51,52].
HDV is divided into eight major genotypes differing as much as 40% in nucleotide sequence [53,54]. 
Genotype I is the most frequent genotype worldwide and has broad spectrum of pathogenicity [6,35]. 
We can see genotype I of HDV in Europe, Middle East, North America and North Africa [3]. Genotype 
I HDV and genotype C HBV infections were associated with more severe outcomes such as the devel-
opment of cirrhosis, hepatocellular carcinoma (HCC) or mortality due to hepatic failure than genotype 
II in Taiwan [55]. Genotype I has two subtypes; IA is predominant in Asia and IB in the US and both 
are common in the Mediterranean area[6]. Genotype II and IV are seen in East Asia usually with mild 
disease [56]. Genotype IIB subtype from patients in Miyako Island and Okinawa have caused more 
severe disease than genotype IIB subtype from Taiwan [57]. HDV genotype III is seen exclusively in 
the Northern part of South America (Columbia, Venezuela, Peru) [3,6]. Genotype III has been associ-
ated with outbreaks of severe and fulminant hepatitis and coexisting genotype F of HBV [6,35]. HDV 
genotype V and VII can be seen in Africa [3]. Le Gal et al. identified an eighth HDV clade (HDV-VIII) 
from 3 complete sequences obtained from strains isolated from patients of African origin in France in 
2006 [54]. While the genotypes of HBV don’t seem to affect the interaction between HBV and HDV, 
the genotypes of HDV may influence the efficiency of assembly with the HBsAg into virions. Therefore, 
further studies are necessary to clarify wether clinical differences among the genotypes exist for replica-
tion, infectivity and pathogenity [6,35].
Pathogenesis
The mechanisms occurring during the course of HDV infection remain unclear. Hepatitis D is mostly 
an immune-mediated disease, but there are some evidence that HDV infection is a cytopathic disease 
[3]. During the acute phase of HDV infection, HDV viremia is associated with an increased level of 
transaminases and low HBV-DNA level, whereas chronic phase is characterized by decreased HDV, 
reactivation of HBV and mild or moderate transaminitis. The late phase consists of remission with 
clearance of these viruses or with the development of cirrhosis or hepatocellular carcinoma due to 
replication of HBV or HDV [1,2,5].
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Innate and adaptive immune responses of host have important roles for the viral clearance and the liver 
disease, but the precise mechanisms for the pathogenesis are not fully understood.
Clinical Features
Presentation of acute HDV infection could be coinfection with HBV or superinfection in a patient with 
established HBV infection. Acute HBV and HDV coinfection can range from mild hepatitis to usually 
severe acute liver failure and results in complete viral clearance in more than 90% of patients. The rate 
of chronicity after coinfection with HBV and HDV is less or similar to that of HBV infection alone 
(less than 10%). HDV superinfection results in chronic HDV infection in 70-90% of HBV carriers. At 
initial histological evaluation, liver biopsies usually have shown severe hepatitis with advanced fibro-
sis. These patients have the risk of rapid progression to cirrhosis and hepatic decompensation causing 
death [3,5,58]. Persistent HDV replication leads to cirrhosis and hepatocellular carcinoma at annual 
rates equal to 4% and 2.8%, respectively, therefore antiviral therapy is indicated in these patients with 
high viral load [59]. Niro et al. revealed that lack of antiviral therapy, cirrhosis at presentation and male 
gender were correlated with poor prognosis in patients from Italy with chronic HDV infection for a 
mean of 9.6 ± 7.7 years of follow-up [60].
Diagnosis
Every patient who is HBsAg+ must be tested for anti-HDV IgG antibodies. The occurrence of anti-HDV 
antibodies is universal in patients with HDV. Anti-HDV antibodies can either disappear after recovery 
from infection or persist even after the patient has cleared HDV or after liver transplantation. Active 
HDV infection is confirmed by the detection of serum HDV-RNA with sensitive real-time PCR. Assays 
of HDV-RNA might return false negative results due to the variability of the genome sequence. In these 
cases testing of anti-HDV IgM could be useful for the diagnosis of active HDV infection [1,3,5]. There-
fore international standardization of the HDV-RNA is necessary to have correct results. Quantification 
of HDV-RNA is not correlated with any clinical parameter or the stage of the liver disease, but is useful 
to evaluate the antiviral therapy [3,5,61,62]. After the identification of HDV-RNA, liver biopsy must 
be performed to evaluate staging and grading of liver disease. As coinfection with HCV and HIV is 
very common, the presence of anti-HCV and anti-HIV antibodies must be checked. In addition, HBV-
DNA quantification, HBeAg and anti-HBe antibody determination must be performed to evaluate the 
chronic HBV infection in chronic HDV infection.
HDV genotyping is usually available in some of the research laboratories. Genotyping could give some 
prediction about the disease progress. As previously noted, genotype I is the most frequent genotype 




Patients with chronic HDV infection have a much higher risk of developing end-stage liver disease 
than those with HBV alone. Delta virus-related hepatitis is a difficult-to-treat disease. Acute HDV in-
fection may present coinfection with HBV infection or in a patient with established HBV infection (su-
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perinfection). Clinical manifestations of HBV and HDV coinfection could range from mild to severe 
fulminant hepatitis. If fulminant hepatitis occurs during the acute hepatitis D, liver transplantation is 
the only treatment option [3,5,6,63].
At present, interferon is the only option for the treatment of chronic hepatitis D. Since most patients 
have advanced disease and cirrhosis, the response rate to interferon (IFN) therapy is not high (less than 
10% with 1-year IFN therapy [63-65]). Therapeutic efficacy increases when higher dose of interferon 
alpha is administered for prolonged periods (12-24 months) [63-66]. As described in an interesting 
case report a 12-year high-dose IFN treatment resulted in the complete resolution of HDV infection 
with remission of liver fibrosis and disappearance of HBV and HDV from serum [67]. We also investi-
gated the 2-year IFN therapy with or without ribavirin in 31 patients with chronic HDV infection [68]. 
In our study, virological response was achieved at a median of 12 months (range = 10-20 months) in 
the IFN monotherapy group. Virologic response was 20% at the end of follow-up period in the IFN 
monotherapy group. In the IFN and ribavirin combination group, 8 out of 16 end-of-therapy respond-
ers cleared the virus after 1 year of therapy. We had emphasized that 1 year of IFN therapy had not been 
sufficient in nearly 50% of patients with chronic HDV infection. However, high doses of IFN alpha and 
prolonged treatment are tolerated only by a minority of patients, probably due to advanced liver disease 
in HDV infection.
After the development of pegylated-IFN (peg-IFN) with improved pharmacokinetics, better out-
comes have been reported with peg-IFN both in naïve and in previous nonresponders to IFN stan-
dard treatments [61,62,69]. Castelnau et al. studied peg-IFN alpha-2b (1.5 µg/kg per week) therapy 
for 12 months in 14 patients with chronic delta hepatitis. They found sustained virological response 
in 43% of patients. Negativity of HDV-RNA at 6 months of therapy was suggested as a predic-
tor for sustained response. Authors emphasized the importance of measurement of HDV-RNA by 
real-time quantitative PCR assay during follow-up [61]. In Edhardt’s study with peg-IFN alpha-2b, 
sustained response was achieved in 2 out of 12 patients (17%) with HDV infection and research-
ers identified nonresponders as those having less than 3 log decrease of HDV-RNA at 6 months of 
treatment [62]. With more knowledge on the basis of HDV-RNA kinetics, we can decide the dura-
tion of therapy more properly. Another study with peg-IFN for 72 weeks detected the sustained 
response rate in 21% out of 38 patients in chronic HDV infection [69]. This response rate is lower 
than the study by Castelnaue et al., probably due to the high prevalence of cirrhosis (28/38, 73%) 
in this study [61].
Several nucleos(t)ide analogs effectively used for HBV infection were found ineffective in the treatment 
of HDV infection [3,65,70].
Lamivudine and famciclovir had no significant antiviral activity against HDV infection [70-72].
Ribavirin was shown to be able to inhibit HDV replication in primary woodchuck hepatocyte cultures 
infected with HDV [73], but ribavirin had no effect on the viral clearance rate with standard IFN or 
peg-IFN in patients with chronic delta hepatitis [61,68,69,74]. Clevudine, another nucleoside analog, 
had significantly decreased HDV-RNA in woodchucks infected with HDV [75].
Clevudine was tried in six patients with HDV infection in a pilot study. Only five of these patients 
could have used clevudine for 9-12 months and clevudine had no effect in terms of HBsAg, ALT and 
HDV-RNA levels [76]. In addition, clevudine could cause severe myopathy by depletion of mitochon-
drial DNA as side effect [77].
A multicenter randomized study (HIDIT I) compared the efficacy of peg-IFN alpha-2a plus adefovir 
versus peg-IFN alpha-2a plus placebo versus adefovir in chronic HDV infection [78]. 72-week results 
of this study showed that peg-IFN alpha-2a had a significant antiviral effect for HDV in more than 
40% of patients, HDV-RNA relapse had occurred in only 1 patient, and 8 additional patients receiving 
peg-IFN had become negative after stopping therapy. Adefovir had not affected HDV replication but 
combination therapy of peg-IFN and adefovir had some advantages in terms of reduction of HBsAg 
235Reviews in Health Care 2012; 3(4)© SEEd All rights reserved
F. GunsarDelta Hepatitis
levels [78]. An international study group had found positive correlation between the HBsAg levels and 
HDV viremia in chronic HDV infection [79].
Therefore combination therapies with peg-IFN and nucleos(t)ide analogs, which are more potent than 
adefovir, could have advantages in the therapy of HDV infection.
There is a case report with resolution of HDV infection with 1-year combination therapy of peg-IFN, 
tenofovir and emtricitabine [80].
A trial with tenofovir and peg-IFN combination therapy is still ongoing and will provide informations 
to take more precise decisions about the combination therapies. Some of the most relevant trials about 
the therapy of chronic HDV infection are summarized in Table I.
Liver transplantation is the best treatment option for end-stage liver disease in HDV infection as in 












Farci et al, 
1994 [64]
42 14 IFN alpha-2a 3 MIU TIW 48 EOT: HDV-RNA- 36% and 71% of pts
Relapses in all pts14 IFN alpha-2a 9 MIU TIW
13 Control: no treatment
Gaudin et al, 
1995 [65]
22 11 IFN alpha-2a 5 MIU/m2 
for 4 months, then  
3 MIU/m2 control
48 EOT: HDV-RNA- 66% of pts,
EOF: HDV-RNA- 9% of pts
11 Control
Madejon et al, 
1994 [66]
26 12 IFN alpha-2a TIW
18 MIU for 6 months,
9 MIU and 6 MIU for 1 
month 3 MIU for 4 months
48 EOT: HDV-RNA- 50% and 19% of pts
EOF: relapses in all pts
14 3 MIU for 12 months
Gunsar et al, 
2005 [68]
31 10 9 MIU IFN alpha-2a TIW 96 EOT: HDV-RNA- 52% of pts
EOF: HDV-RNA- 24% of pts
Ribavirin has no beneficial effect
21 IFN + ribavirin 
(1000-1200 mg/day)
Niro et al, 
2006 [69]
38 16 Peg-IFN alpha-2b 1.5μg/kg 72 EOT: HDV-RNA- 13% of pts
EOF: HDV-RNA- 21% of pts
Ribavirin has no beneficial effect




39 17 9 MIU IFN alpha-2a TIW 48 EOF: HDV-RNA-
• Lam group: 12%
• Lam + IFN: 36%
• IFN: 50%
Lam has no beneficial effect
14 Lam 100 mg/d
8 Lam 100 mg/d+ 9 MIU IFN 
alpha-2a TIW
Wedemeyer 
et al, 2011 
[78]
90 29 Peg-IFN alpha-2a 180 μg/w 48 EOF: HDV-RNA-
• Peg-IFN group: 31%
• Peg-IFN + ADV: 26% of pts
• ADV: 0%
Combination therapy was found 
better in terms of decreasing the 
HBsAg levels
31 Peg-IFN alpha-2a 180 μg/w 
+ ADV
30 ADV 10mg/day
Table I. Review of treatment of chronic delta hepatitis
ADV = adefovir; d = day; EOF = end of follow-up; EOT = end of treatment; IFN = interferon; Lam = lamivudin; 
MIU = million units; Peg-IFN = pegylated interferon; pts = patients; TIW = three times in a week; w = week
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the risk of re-infection is significantly lower for HDV than for HBV and/or HCV. Five-year survival 
rates are significantly higher in patients with HDV cirrhosis than in patients undergoing transplanta-
tion for the other causes of liver cirrhosis [63,81].
 • Treatment of chronic delta hepatitis is really one of the most difficult issues in hepatology. Treat-
ment failures might result from the interference of HDV with IFN alpha intracellular signaling 
and the severe histology [35,82]. The problem in HDV therapy is that there is no specific enzy-
matic function to target, such as the polymerases and proteases of HBV and HCV. HDV activity, 
in fact, depends on the HBsAg and not on HBV replication or on the level of HBV-DNA [35]. 
The new agents preventing the association of the HDV ribonucleoprotein with the HBsAg might 
form the basis of a new therapeutic area in chronic hepatitis D. The large antigen contains at its 
carboxyl terminus a cystein with four amino acid motifs. These motifs serve as substrate for pre-
nyl transferases, which add a prenyl group to the large antigen. It has been shown that prenylation 
of large antigen is necessary for HDV replication [83]. Prenylation inhibitors have been used for 
treatment of malignancies and have been found to be safe in this setting [3,35]. Therefore, pre-
nylation inhibitors have been investigated in chronic HDV infection. Bordier et al. provided the 
first preclinical data supporting the in vivo efficacy of prenylation inhibition as a novel antiviral 
therapy with potential application to HDV [84]. Using glucosidase inhibitors in HDV infection 
could prevent the secretion of virions from the 
hepatocytes, but these molecules may stimulate 
oncogenic pathways in terms of hepatocellular 
carcinoma [85,86]. New agents that can affect 
the interactions between the large HDV antigen 
and HBsAg in the HDV virion will be a hope 
in treatment of HDV infection [35]. Nowadays, 
peg-IFN is the only agent used as first-line ther-
apy in chronic HDV infection in naïve patients 
or nonresponders to standard IFN therapy. Mea-
suring the kinetics of HDV-RNA during therapy 
will give some advantages to identify who needs 
extended therapy or who is nonresponder.
The review in brief
Clinical question Delta hepatitis is a health problem in the world, being the virus highly endemic in Mediterranean 
countries, the Middle East, Central Africa and Northern parts of South America. After the HBV 
vaccination programs in many countries all over the world, HDV infection has decreased since 1980’s, 
but this decline has not continued further in the last decade, particularly in Europe. Immigrants from 
endemic areas, parenteral drug users and the patients who could not respond to therapy for HDV are 
still reservoir for disease transmission. HDV infection is too difficult to treat. This paper about delta 
hepatitis is a narrative review
Type of review Narrative
Search of the 
literature
Search on PubMed for all the most recent articles on delta hepatitis, with keywords: delta hepatitis, 
epidemiology, treatment, and delta virus
Conclusions Nowadays, pegylated IFNs are only options for the treatment. The new agents preventing the 
association of the HDV ribonucleoprotein with the HBsAg might form the basis of a new therapeutic 
area in chronic hepatitis D. Therefore prenylation inhibitors and combination therapy with pegylated 
interferon and tenofovir have been investigated in the treatment of chronic HDV infection
Limitations
After the HBV vaccination programs in many countries all over the world, HDV infection has de-
creased since 1980’s, but this decline has not continued further in the last decade, particularly in Eu-
rope, probably due to migration from the endemic regions [87]. Parenteral drug users and the patients 
who could not respond to therapy for HDV are still reservoir for disease transmission. As HDV infec-
tion is too difficult to treat, there are many patients expecting the new therapies. Therefore HDV infec-
tion is still an important public health problem in the world. We need much more studies to under-
stand the molecular mechanisms of HDV to manage the disease and acquire better therapy responses 
in HDV infection.
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Questions for further research
Duration, dosage of pegylated interferon 
and termination rules according to HDV-
RNA kinetics are not defined clearly. The 
results of studies about HDV-RNA kinetics 
which can be used as road map during the-
rapy are needed.
The studies about the therapy preventing 
the association of the HDV ribonucleopro-
tein with the HBsAg will be hope for the 
new agents for this difficult disease.
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After the HBV vaccination programs in many countries all over the world, HDV infection has de-
creased since 1980’s, but this decline has not continued further in the last decade, particularly in Eu-
rope, probably due to migration from the endemic regions [87]. Parenteral drug users and the patients 
who could not respond to therapy for HDV are still reservoir for disease transmission. As HDV infec-
tion is too difficult to treat, there are many patients expecting the new therapies. Therefore HDV infec-
tion is still an important public health problem in the world. We need much more studies to under-
stand the molecular mechanisms of HDV to manage the disease and acquire better therapy responses 
in HDV infection.
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